Archive for the ‘ Test Stimulants ’ Category
Amgen Xgeva receives FDA approval
Amgen has stated that the US Food and Drug Administration (FDA) has approved Xgeva (denosumab), a RANK Ligand inhibitor for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors, following a 6 month priority review. The FDA approval of Xgeva is based on the results of three pivotal, Phase 3 [...]
